Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
CTX-471 by Compass Therapeutics for Head And Neck Cancer: Likelihood of Approval
CTX-471 is under clinical development by Compass Therapeutics and currently in Phase I for Head And Neck Cancer. According to...
Data Insights
Risk adjusted net present value: What is the current valuation of Compass Pathways's CTX-471?
CTX-471 is a monoclonal antibody commercialized by Compass Pathways, with a leading Phase I program in Head And Neck Cancer....